Targeting of RecQ Helicases as a Novel Therapeutic Strategy for Ovarian Cancer.

Abstract

RecQ helicases are essential for DNA replication, recombination, DNA damage repair, and other nucleic acid metabolic pathways required for normal cell growth, survival, and genome stability. More recently, RecQ helicases have been shown to be important for replication fork stabilization, one of the major mechanisms of PARP inhibitor resistance. Cancer cells often have upregulated helicases and depend on these enzymes to repair rapid growth-promoted DNA lesions. Several studies are now evaluating the use of RecQ helicases as potential biomarkers of breast and gynecologic cancers. Furthermore, RecQ helicases have attracted interest as possible targets for cancer treatment. In this review, we discuss the characteristics of RecQ helicases and their interacting partners that may be utilized for effective treatment strategies (as cancers depend on helicases for survival). We also discuss how targeting helicase in combination with DNA repair inhibitors (i.e., PARP and ATR inhibitors) can be used as novel approaches for cancer treatment to increase sensitivity to current treatment to prevent rise of treatment resistance.

• Authors: Jyotirindra Maity, Sachi Horibata, Grant Zurcher, Jung-Min Lee
• Journal: Cancers (Cancers (Basel)) Vol. 14 Issue 5 (Feb 26 2022) ISSN: 2072-6694 [Print] Switzerland
• PMID: 35267530 (Publication Type: Journal Article, Review)